Cargando…

Recent advances in medical therapy for metastatic urothelial cancer

Cytotoxic chemotherapy has been the mainstay of medical therapy for metastatic urothelial cancer. Currently, the gemcitabine/cisplatin regimen is widely used worldwide as the standard first-line medical treatment. Very recently, in 2017, pembrolizumab, a highly selective, humanized monoclonal IgG4κ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuasa, Takeshi, Urakami, Shinji, Yonese, Junji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097083/ https://www.ncbi.nlm.nih.gov/pubmed/29556919 http://dx.doi.org/10.1007/s10147-018-1260-0

Ejemplares similares

Denosumab: a new option in the treatment of bone metastases from urological cancers
por: Yuasa, Takeshi, et al.
Publicado: (2012)

Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single‐center analysis in Japan
por: Fujiwara, Motohiro, et al.
Publicado: (2021)

A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome
por: Oki, Ryosuke, et al.
Publicado: (2022)

A case of sequential medical therapy for advanced ureteral cancer in Li–Fraumeni syndrome
por: Une, Minami, et al.
Publicado: (2023)

Recent Advances in Medical Therapy for Urological Cancers
por: Yuasa, Takeshi, et al.
Publicado: (2022)

Clinical outcome of patients with pancreatic metastases from renal cell cancer
por: Yuasa, Takeshi, et al.
Publicado: (2015)

Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high
por: Fujiwara, Motohiro, et al.
Publicado: (2020)

Long-term complete response of antiandrogen withdrawal syndrome in a patient with metastatic prostate cancer: A case report
por: Sano, Masayuki, et al.
Publicado: (2016)

Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma
por: Katims, Andrew B., et al.
Publicado: (2022)

Biomarkers to predict prognosis and response to checkpoint inhibitors
por: Yuasa, Takeshi, et al.
Publicado: (2017)

Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study
por: Fukushima, Hiroshi, et al.
Publicado: (2020)

Therapeutic inhibition of mitochondrial function induces cell death in starvation-resistant renal cell carcinomas
por: Isono, Takahiro, et al.
Publicado: (2016)

Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer
por: Uehara, Sho, et al.
Publicado: (2015)

Impact of Serum γ-Glutamyltransferase on Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel
por: Une, Minami, et al.
Publicado: (2021)

A case of gastric metastasis from renal cell cancer during the sequential targeted therapy
por: Uehara, Sho, et al.
Publicado: (2017)

Diagnostic performance of a computer-assisted diagnosis system for bone scintigraphy of newly developed skeletal metastasis in prostate cancer patients: search for low-sensitivity subgroups
por: Koizumi, Mitsuru, et al.
Publicado: (2017)

Longitudinal change in health-related quality of life after intensity-modulated radiation monotherapy for clinically localized prostate cancer
por: Yamamoto, Shinya, et al.
Publicado: (2013)

Unusual metastasis from renal cell cancer after partial nephrectomy and sequential targeted therapy
por: Yasuoka, Shotaro, et al.
Publicado: (2021)

Comparison Between Dose-Escalated Intensity Modulated Radiation Therapy and 3-Dimensional Conformal Radiation Therapy for Salvage Radiation Therapy After Prostatectomy
por: Shimoyachi, Nana, et al.
Publicado: (2021)

Precision Medicine in the Treatment of Locally Advanced or Metastatic Urothelial Cancer: New Molecular Targets and Pharmacological Therapies
por: Vitiello, Antonio, et al.
Publicado: (2022)

Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan
por: Fontes, Mariane S, et al.
Publicado: (2022)

Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context
por: Hoffman-Censits, Jean, et al.
Publicado: (2022)

Relationship of B7-H3 expression in tumor cells and tumor vasculature with FOXP3+ regulatory T cells in renal cell carcinoma
por: Inamura, Kentaro, et al.
Publicado: (2019)

The utility of diffusion‐weighted whole‐body imaging with background body signal suppression in detecting metastatic lesion of germ cell carcinoma
por: Yoshitomi, Kasumi Kaneko, et al.
Publicado: (2021)

Early onset recall pneumonitis during targeted therapy with sunitinib
por: Yuasa, Takeshi, et al.
Publicado: (2013)

Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma
por: Matsubara, Nobuaki, et al.
Publicado: (2022)

Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer
por: Morrow, Phuong Khanh H, et al.
Publicado: (2009)

Editorial Comment to Testicular metastasis from urothelial carcinoma of the bladder
por: Yuasa, Takeshi
Publicado: (2021)

Molecular Targeted Therapies in Metastatic Prostate Cancer: Recent Advances and Future Challenges
por: Sorrentino, Carlo, et al.
Publicado: (2023)

Emerging agents for the treatment of metastatic urothelial cancer
por: Kwon, Whi-An, et al.
Publicado: (2021)

Erdafitinib for locally advanced or metastatic urothelial carcinoma
por: Siefker-Radtke, Arlene O, et al.
Publicado: (2022)

Abundance of TRAIL attenuated by HIF2α and c-FLIP affects malignancy in renal cell carcinomas
por: Isono, Takahiro, et al.
Publicado: (2018)

De novo large‐cell neuroendocrine carcinoma of the prostate: A case report and literature review
por: Fukagawa, Eri, et al.
Publicado: (2022)

Gender-specific outcomes in immune checkpoint inhibitor therapy for advanced or metastatic urothelial cancer: a systematic review and meta-analysis
por: Schneidewind, Laila, et al.
Publicado: (2023)

Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options
por: Park, Inkeun, et al.
Publicado: (2020)

Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab
por: Yamasaki, Mutsushi, et al.
Publicado: (2016)

Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers
por: Rizzo, Mimma, et al.
Publicado: (2021)

Update on the Treatment of Metastatic Urothelial Carcinoma
por: Bukhari, Nedal, et al.
Publicado: (2018)

Editorial: Recent Advances in Diagnosis and Management of Urothelial Carcinoma
por: Ku, Ja Hyeon, et al.
Publicado: (2021)

Optimizing frontline therapy in advanced urothelial cancer
por: Kwon, Whi-An, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kum55u94bms3okqn2bocg505aq